---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-26-000100"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2026-08-06T11:15:24+00:00"
generated_at: "2026-08-06T11:20:21.902468+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q1 FY2026 net loss of $153.2M; cash $797.8M, pipeline on track

## Summary
- Net loss of $153.2M ($0.75/share) vs $120.6M ($0.71/share) YoY; non-GAAP net loss $139.4M.
- Cash and equivalents $797.8M as of June 30, 2026, providing runway to potential IMVT-1402 launch in Graves' disease.
- R&D expenses $142.6M (GAAP) vs $101.2M YoY, driven by IMVT-1402 clinical trial costs.
- Pipeline on track: topline data for D2T RA and CLE in H2 2026; GD and MG in 2027; CIDP and SjD in 2028.
- G&A expenses decreased to $17.7M from $26.0M YoY.

## SEC filing metadata
- accession: 0001764013-26-000100
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2026-08-06T11:15:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/0001764013-26-000100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401326000100/imvt-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-26-000100
- JSON: https://secwatch.observer/filing/0001764013-26-000100.json
- Plain text: https://secwatch.observer/filing/0001764013-26-000100.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.